@FiercePharma: ICYMI yesterday: Ireland plant with 100 workers on Sun's list for sale or closure. Item | Follow @FiercePharma
@EricPFierce: Sun targets Ranbaxy plant in Ireland as it prepares to trim manufacturing network. FiercePharmaManufacturing story | Follow @EricPFierce
@CarlyHFierce: Icahn casts his eye on Vivus with tender offer for convertible notes. More | Follow @CarlyHFierce
> Greece lifted its ban on re-export of a range of medications, instituted in July on worries of drug shortages during the country's financial crisis. Report
> U.K. cost-effectiveness watchdogs are preparing to recommend seven biologic treatments for rheumatoid arthritis, including two biosimilar meds. Report
> The market for snake antivenom in the U.S.--where prices can be more than $14,000 per vial, compared with a few hundred in other countries--illustrates the "broken" nature of the American system of paying for drugs, a researcher said. Report
> Pharmacy beneifts manager Express Scripts said its CEO, George Paz, would retire in May, to be replaced by its current president, Tim Wentworth. Report
> India may join a Geneva-based inspection cooperative to allow drug exporters to avoid multiple regulatory visits, but the effort could require some drugmakers to upgrade their manufacturing facilities. Report
Medical Device News
@FierceMedDev: Biogen CEO says the biotech aims to develop wearable and ingestible devices. More | Follow @FierceMedDev
@VarunSaxena2: Robotic surgery aspirant receives $4M+ in equity financing. Story | Follow @VarunSaxena2
@EmilyWFierce: ICYMI from FiercePharma: Roche CEO: Despite China worries, emerging markets will continue to deliver growth. Article | Follow @EmilyWFierce
> JAMA: Women face increased risk for second vaginal mesh surgery 10 years after implant. More
> Delphinus raises $39M+ to back pivotal trial of more effective dense breast tissue ultrasound imaging. Article
Biotech News
@FierceBiotech: Penn scientists identify viral products that defend against respiratory syncytial virus. FierceBiotechResearch story | Follow @FierceBiotech
@JohnCFierce: Who you going to buy? Gilead banks $10B, stirring fresh buzz about a blockbuster buyout. Article | Follow @JohnCFierce
@DamianFierce: Flemming Ornskov, "avid postcard and letter writer" who keeps up on household chores. More | Follow @DamianFierce
> Clovis leaps as AstraZeneca's AZD9291 disappoints on lung cancer. Story
> CureVac turns to Cambridge, MA, to jump-start its mRNA pipeline. Item
> IBM debuts its hotly hyped 'cognitive cloud' health HQ in Cambridge. Article
> Takeda bets $500M on a freshly unstealthed biotech. Report
Vaccines News
> UC Berkeley scientists identify protein that causes dengue shock as a potential vaccine target. Item
> With limited ACIP nod, U.S. universities take different approaches to Pfizer, GSK MenB jabs. Report
> VBI Vaccines scores up to $265,000 from Canadian organization for RSV vaccine. Story
> Analysis: Sanofi's Fluzone High Dose for adults 65+ results in lower medical costs. Article
> Merck's Zostavax not cost-effective for those in their 50s: Study. More
CRO News
> Aragen licenses a protein technology to speed up biologics R&D. Item
> Rho snags a $120M federal contract with NIH. Story
> Recipharm signs on to make LobSor's Parkinson's drug as it negotiates with Novartis. Article
> Icon teams up with IBM to accelerate clinical trial startup. News
> Surging dollar blunts Catalent's revenue, but profits soar in fiscal '15. Article
Pharma Manufacturing News
> Bangladesh-based Square Pharmaceuticals has two new plants online. Item
> Canada allows Apotex Indian plants to regain access to its markets. More
> GSK recalls more than 425K tubes of antibiotic cream. Report
> Sun targets Ranbaxy plant in Ireland as it prepares to trim manufacturing network. Article
> Glaxo starts $153M plant in India. Story
Pharma Asia News
> Japan's Takeda gets U.S. FDA priority review for ixazomib. Item
> FT counts 39 plants banned in India as regulatory woes mount for drugmakers. More
> China Daily carries lengthy industry-linked op-ed against overuse of stents. Report
> Apotex sees Health Canada lift ban on two India plants. Story
> Chugai and Roche get U.S. FDA priority review on alectinib. Article
And Finally... A consumer test for cancer DNA hit the market amid worries about its interpretation. Report